Circulating tumour markers can define patients with normal colons, benign polyps, and cancers
2011

Circulating DNA as a Diagnostic Tool for Colorectal Cancer

Sample size: 85 publication Evidence: moderate

Author Information

Author(s): Mead R, Duku M, Bhandari P, Cree I A

Primary Institution: Queen Alexandra Hospital, Portsmouth

Hypothesis

Can circulating free DNA (cfDNA) markers improve the diagnosis of colorectal cancer and benign polyps?

Conclusion

Circulating markers in combination with other markers could lead to a simple blood test for colorectal cancer and polyps.

Supporting Evidence

  • The best model showed an ROC curve of 0.855 for diagnosing polyps and cancer.
  • Patients with benign polyps had significantly raised levels of total DNA compared to normal controls.
  • Total DNA was the best single marker for distinguishing cancer from normal in this study.

Takeaway

Doctors can use a blood test to check for cancer and polyps in the colon, which is easier than other tests.

Methodology

The study analyzed cfDNA from blood samples of 85 patients using PCR and CEA measurements.

Limitations

The test lacks specificity for colorectal cancer and requires validation in larger populations.

Participant Demographics

Patients included 35 without endoscopic abnormality, 26 with benign adenomas, and 24 with colorectal carcinomas.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1038/bjc.2011.230

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication